Literature DB >> 33654738

Expression and Purification of Adeno-associated Virus Virus-like Particles in a Baculovirus System and AAVR Ectodomain Constructs in E. coli.

Nancy Meyer1,2, Omar Davulcu1,3, Qing Xie1,4, Mark Silveria5, Grant M Zane5, Edward Large5, Michael S Chapman1,5.   

Abstract

Adeno-associated virus (AAV) is a promising gene therapy vector and the biophysical characterization of its interactions with host proteins is a critical foundation for engineering tissue targeting and immune escape. Presented here are protocols for the production of: (a) the outer protein shells (virus-like particles or VLPs) for serotype 2 (AAV-2) and (b) two fragments from the binding ectodomain of AAV's cellular receptor, AAVR. His6PKD1-2 comprises the first two polycystic kidney disease (PKD) domains, the minimal required for efficient binding of AAV, expressed with an N-terminal histidine tag. MBP-PKD1-5 is a fusion of the maltose binding protein with all five of the PKD domains of the AAVR receptor. Presented are the expression and purification of milligram quantities, ample for in vitro analyses. For AAV-2, the protocol offers an alternative to the use of (infectious) wild-type virus or transducing vectors. One of the methods for producing transducing vector is in Sf9 cells, and the production of VLPs is based on this. For AAVR, the protocols enable biochemical and biophysical characterization of virus-binding. The minimal two-domain construct allows more saturated binding to symmetry-equivalent sites on the virus, while the larger construct might be better expected to reflect the native receptor.
Copyright © The Authors; exclusive licensee Bio-protocol LLC.

Entities:  

Keywords:  AAV; AAVR; Adeno-associated virus; Co-receptor; Gene therapy; Viral entry; Virus; Virus receptor

Year:  2020        PMID: 33654738      PMCID: PMC7842819          DOI: 10.21769/BioProtoc.3513

Source DB:  PubMed          Journal:  Bio Protoc        ISSN: 2331-8325


  35 in total

Review 1.  Engineering the AAV capsid to optimize vector-host-interactions.

Authors:  Hildegard Büning; Anke Huber; Liang Zhang; Nadja Meumann; Ulrich Hacker
Journal:  Curr Opin Pharmacol       Date:  2015-08-25       Impact factor: 5.547

2.  Single amino acid modification of adeno-associated virus capsid changes transduction and humoral immune profiles.

Authors:  Chengwen Li; Nina Diprimio; Dawn E Bowles; Matthew L Hirsch; Paul E Monahan; Aravind Asokan; Joseph Rabinowitz; Mavis Agbandje-McKenna; R Jude Samulski
Journal:  J Virol       Date:  2012-05-16       Impact factor: 5.103

3.  Structure of adeno-associated virus serotype 8, a gene therapy vector.

Authors:  Hyun-Joo Nam; Michael Douglas Lane; Eric Padron; Brittney Gurda; Robert McKenna; Erik Kohlbrenner; George Aslanidi; Barry Byrne; Nicholas Muzyczka; Sergei Zolotukhin; Mavis Agbandje-McKenna
Journal:  J Virol       Date:  2007-08-29       Impact factor: 5.103

4.  Purification of recombinant adeno-associated virus by iodixanol gradient ultracentrifugation allows rapid and reproducible preparation of vector stocks for gene transfer in the nervous system.

Authors:  W T Hermens; O ter Brake; P A Dijkhuizen; M A Sonnemans; D Grimm; J A Kleinschmidt; J Verhaagen
Journal:  Hum Gene Ther       Date:  1999-07-20       Impact factor: 5.695

5.  Successful Repeated Hepatic Gene Delivery in Mice and Non-human Primates Achieved by Sequential Administration of AAV5ch and AAV1.

Authors:  Anna Majowicz; David Salas; Nerea Zabaleta; Estefania Rodríguez-Garcia; Gloria González-Aseguinolaza; Harald Petry; Valerie Ferreira
Journal:  Mol Ther       Date:  2017-06-05       Impact factor: 11.454

6.  Adeno-associated virus 2 bound to its cellular receptor AAVR.

Authors:  Ran Zhang; Lin Cao; Mengtian Cui; Zixian Sun; Mingxu Hu; Rouxuan Zhang; William Stuart; Xiaochu Zhao; Zirui Yang; Xueming Li; Yuna Sun; Shentao Li; Wei Ding; Zhiyong Lou; Zihe Rao
Journal:  Nat Microbiol       Date:  2019-02-11       Impact factor: 17.745

7.  Bioengineered AAV Capsids with Combined High Human Liver Transduction In Vivo and Unique Humoral Seroreactivity.

Authors:  Nicole K Paulk; Katja Pekrun; Erhua Zhu; Sean Nygaard; Bin Li; Jianpeng Xu; Kirk Chu; Christian Leborgne; Allison P Dane; Annelise Haft; Yue Zhang; Feijie Zhang; Chris Morton; Marcus B Valentine; Andrew M Davidoff; Amit C Nathwani; Federico Mingozzi; Markus Grompe; Ian E Alexander; Leszek Lisowski; Mark A Kay
Journal:  Mol Ther       Date:  2017-09-25       Impact factor: 11.454

8.  Efficacy and long-term safety of alipogene tiparvovec (AAV1-LPLS447X) gene therapy for lipoprotein lipase deficiency: an open-label trial.

Authors:  D Gaudet; J Méthot; S Déry; D Brisson; C Essiembre; G Tremblay; K Tremblay; J de Wal; J Twisk; N van den Bulk; V Sier-Ferreira; S van Deventer
Journal:  Gene Ther       Date:  2012-06-21       Impact factor: 5.250

9.  The 2.8 Å Electron Microscopy Structure of Adeno-Associated Virus-DJ Bound by a Heparinoid Pentasaccharide.

Authors:  Qing Xie; John M Spear; Alex J Noble; Duncan R Sousa; Nancy L Meyer; Omar Davulcu; Fuming Zhang; Robert J Linhardt; Scott M Stagg; Michael S Chapman
Journal:  Mol Ther Methods Clin Dev       Date:  2017-03-08       Impact factor: 6.698

10.  Structure of the gene therapy vector, adeno-associated virus with its cell receptor, AAVR.

Authors:  Nancy L Meyer; Guiqing Hu; Omar Davulcu; Qing Xie; Alex J Noble; Craig Yoshioka; Drew S Gingerich; Andrew Trzynka; Larry David; Scott M Stagg; Michael Stewart Chapman
Journal:  Elife       Date:  2019-05-22       Impact factor: 8.140

View more
  1 in total

Review 1.  Cryo-electron Microscopy of Adeno-associated Virus.

Authors:  Scott M Stagg; Craig Yoshioka; Omar Davulcu; Michael S Chapman
Journal:  Chem Rev       Date:  2022-05-16       Impact factor: 72.087

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.